Health AI, Unicorns, and Stretched Valuations

In recent years, digital health has been a hot-bed of innovation as companies tackle healthcare inefficiencies with new technology, but the rapidly climbing valuations are causing many to wonder: how much higher can they go?

Healthcare AI raises $8.5b in 2021.

According to a report from CBInsights, private healthcare AI companies have raised $8.5b through the first three quarters of the year, surpassing 2020’s full-year total of $6.6b.

  • Q3 2021 was healthcare AI’s strongest quarter ever ($3.2b raised across 149 rounds)
  • Top areas of focus include remote patient monitoring, decentralized clinical trials, and home diagnostics.
  • AI startups account for approximately 40% of year-to-date digital health funding

Unicorns are no longer endangered.

The term “unicorn” used to indicate that a young company was a successful outlier with a $1b+ valuation, but has recently been diluted as more startups earn the designation.

  • CBInsights now counts the total number of “unicorns” at 925 globally, including 13 healthcare AI companies that received the title just last quarter.
  • When the term unicorn was coined in 2013, there were fewer unicorns than there are “decacorns” with a $10b+ valuation today (45).
  • Devoted Health currently has the highest healthcare company valuation ($12.6b).

How much higher can valuations go?

Digital health companies scaled quickly during the pandemic by taking on outside investment to keep up with the surge in demand, which sent private valuations soaring. Many of these valuations were based on the size of the total addressable market, driven more by potential than current revenue. If these companies fail to capture share, or if health-tech adoption declines as the pandemic wanes, then these expectations might be hard to meet and we could start to see some moderation.

FemTec Health Emerges From Stealth, Acquires Birchbox

Former Livongo executive Dr. Kimon Angelides announced that FemTec Health, a technology-focused women’s health sciences company, is emerging from stealth with $38m in funding and the acquisition of subscription box pioneer Birchbox.

FemTec was originally formed in May 2020 with the aim of using technology to personalize care for women across the health continuum, from specialty and reproductive care to mental health and chronic condition management.

  • At launch, FemTec has over 10m members, two in-progress clinical trials, and 150 employees. Using a combination of AI and predictive analytics, it is looking to create a unified experience for its products and services across multiple channels, including D2C, B2B (employers, health plans), and subscriptions.
  • BiomeAI is the data analytics platform around which most of FemTec’s solutions revolve, which customizes care by using machine learning to transform data (consumer, genetic, microbiome, biometric) into personalized product and treatment recommendations.
  • Key acquisitions have helped FemTec launch with an established member base, such as digital cosmetics store Mira Beauty, social marketing platform Liquid Grid, and beauty box early mover Birchbox. FemTec announced plans to re-launch Birchbox later this year with a focus on BiomeAI-curated skin and healthcare products as opposed to beauty supplies.

The Takeaway

While FemTec is first and foremost a female health company, its acquisition history and BiomeAI recommendation platform show that it will likely focus more on consumer products than other competitors in the space. Female health is a giant market and one that’s been historically underserved, opening up plenty of runway for FemTec to meet unmet demand for personalized care.

Get the top digital health stories right in your inbox